No Data
No Data
Jefferies Maintains Viatris(VTRS.US) With Buy Rating, Cuts Target Price to $13
Jefferies Adjusts Viatris Price Target to $13 From $15, Maintains Buy Rating
Live Stock News: Hard Week Reaching an End, AVGO Shows Semi's Are not Going Down Without a Fight
Biocon Biologics Announces Positive Results From Phase 3 Study of Yesintek Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
Viatris To Go Ex-Dividend On March 10th, 2025 With 0.12 USD Dividend Per Share
Tech Market Turmoil? Here’s Where Smart Investors Might be Looking